Thromboinflammation response to tocilizumab in COVID‐19

BACKGROUND: Coronavirus disease‐19 (COVID‐19) spans a wide spectrum of illness. Severe cases of COVID‐19 can manifest inflammation in organs other than the lung, in tissues not known to support viral replication, and also in a hypercoagulable state. These observations have suggested that severe acut...

Descripción completa

Detalles Bibliográficos
Autores principales: Gergi, Mansour, Cushman, Mary, Littenberg, Benjamin, Budd, Ralph C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles ‐ Thrombosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7537313/
https://www.ncbi.nlm.nih.gov/pubmed/33043232
http://dx.doi.org/10.1002/rth2.12436

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7537313/
https://www.ncbi.nlm.nih.gov/pubmed/33043232
http://dx.doi.org/10.1002/rth2.12436

Ejemplares similares